Skip to main content
Figure 2 | BMC Musculoskeletal Disorders

Figure 2

From: Systemic zoledronate treatment both prevents resorption of allograft bone and increases the retention of new formed bone during revascularization and remodelling. A bone chamber study in rats

Figure 2

A Untreated control graft after 6 weeks in the chamber Ingrowth from openings in the bottom of the chamber and upwards. At the top a vascularized fibrotic tissue has advanced furthest into the graft. The fibrotic tissue(F) is revascularized but the graft trabeculas (G), have not remodelled or started to resorb. The frontier of new-formed bone (NB) advances as a thin rim into the graft, preceeded by osteoclasts (OC). Since the graft is remodelling within a stress-shielded titanium chamber, without any deformation of the tissue, the new-formed bone resorb immediately. Below the new bone, therefore a marrow cavity (M) is formed where both the new-formed as well as the old graft bone is resorbed. (Hematoxylin Eosin × 20). B. Magnification of the borderzone between remodelled and resorbed bon, the front of new formed bone (Hematoxylin Eosin × 100)

Back to article page